Increased rate of complete pathologic response after neoadjuvant FOLFIRINOX for BRCA mutation carriers with borderline resectable pancreatic cancer
T Golan, A Barenboim, G Lahat, I Nachmany… - Annals of Surgical …, 2020 - Springer
Background Neoadjuvant FOLFIRINOX is a standard-of-care treatment for BRPC patients.
Patients with gBRCAm who have demonstrated improved response to platinum-based …
Patients with gBRCAm who have demonstrated improved response to platinum-based …
Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: is radiation necessary in the modern era of chemotherapy?
SS Kim, EK Nakakura, ZJ Wang, GE Kim… - Journal of surgical …, 2016 - Wiley Online Library
Background No consensus exists regarding the optimal neoadjuvant treatment paradigm for
patients with borderline resectable pancreatic cancer (BRPC), including the respective roles …
patients with borderline resectable pancreatic cancer (BRPC), including the respective roles …
[HTML][HTML] Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy compared with gemcitabine-based …
C Yoo, J Kang, KP Kim, JL Lee, BY Ryoo, HM Chang… - Oncotarget, 2017 - ncbi.nlm.nih.gov
Borderline resectable pancreatic cancer (BRPC) is a potentially resectable disease but is
associated with poorer survival compared to primary resectable disease. There has been no …
associated with poorer survival compared to primary resectable disease. There has been no …
Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer: a systematic review and patient-level meta-analysis
QP Janssen, S Buettner, M Suker… - JNCI: Journal of the …, 2019 - academic.oup.com
Background FOLFIRINOX is a standard treatment for metastatic pancreatic cancer patients.
The effectiveness of neoadjuvant FOLFIRINOX in patients with borderline resectable …
The effectiveness of neoadjuvant FOLFIRINOX in patients with borderline resectable …
FOLFIRINOX or gemcitabine-based chemotherapy for borderline resectable and locally advanced pancreatic cancer: a multi-institutional, patient-level, meta-analysis …
D Eshmuminov, B Aminjonov, RF Palm… - Annals of surgical …, 2023 - Springer
Background Pancreatic cancer often presents as locally advanced (LAPC) or borderline
resectable (BRPC). Neoadjuvant systemic therapy is recommended as initial treatment. It is …
resectable (BRPC). Neoadjuvant systemic therapy is recommended as initial treatment. It is …
Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: an intention to treat analysis
A Barenboim, G Lahat, R Geva, I Nachmany… - European Journal of …, 2018 - Elsevier
Objective To assess clinical and pathologic efficacy of neoadjuvant FOLFIRINOX for locally
advanced (LAPC) and borderline resectable pancreatic cancer (BRPC). Methods Patients …
advanced (LAPC) and borderline resectable pancreatic cancer (BRPC). Methods Patients …
Neoadjuvant‐modified FOLFIRINOX vs nab‐paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved …
We conducted an institutional study to compare the clinical and pathological efficacy
between the neoadjuvant therapy (NAT)‐modified FOLFIRINOX (mFOLF) vs nanoparticle …
between the neoadjuvant therapy (NAT)‐modified FOLFIRINOX (mFOLF) vs nanoparticle …
Neoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in borderline resectable pancreatic adenocarcinoma: a Phase 2 study for clinical and …
Background Patients with borderline resectable pancreatic cancer (BRPC) have poor
prognosis with upfront surgery. Methods This was a single-arm Phase 2 trial for clinical and …
prognosis with upfront surgery. Methods This was a single-arm Phase 2 trial for clinical and …
Neoadjuvant treatment in patients with resectable and borderline resectable pancreatic cancer
QP Janssen, EM O'Reilly, CHJ Van Eijck… - Frontiers in …, 2020 - frontiersin.org
Approximately 20% of pancreatic ductal adenocarcinoma (PDAC) patients have (borderline)
resectable pancreatic cancer [(B) RPC] at diagnosis. Upfront resection with adjuvant …
resectable pancreatic cancer [(B) RPC] at diagnosis. Upfront resection with adjuvant …
Neoadjuvant FOLFIRINOX application in borderline resectable pancreatic adenocarcinoma: a retrospective cohort study
Fluorouracile, oxaliplatin, irinotecan, and leucovorin (FOLFIRINOX) has not been
extensively used in the neoadjuvant setting because of concerns with safety and toxicity. We …
extensively used in the neoadjuvant setting because of concerns with safety and toxicity. We …
相关搜索
- neoadjuvant folfirinox increased rate
- neoadjuvant folfirinox mutation carriers
- mutation carriers increased rate
- borderline resectable pancreatic cancer
- neoadjuvant folfirinox patient level
- borderline resectable patient level
- neoadjuvant folfirinox radiation therapy
- borderline resectable meta analysis
- pancreatic cancer patient level
- neoadjuvant folfirinox meta analysis
- pancreatic cancer meta analysis
- borderline resectable nab paclitaxel
- neoadjuvant folfirinox efficacy and safety
- borderline resectable cancer patients
- neoadjuvant folfirinox rate gemcitabine
- borderline resectable surgical resection